Outcome evaluation of therapeutic community model in Iran

International Journal of Health Policy and Management

Volumn 1, Issue 2, 2013, Pages 131-135

  Sadir, Nasrindokht ^a   Shojaei, Mojtaba ^b   Moadab, Kamaladdin ^b   Abbasi, Reza ^b   Bahrampour, Abbas ^c   Nakhaee, Nouzar ^d  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Kerman Social Security Organization   (Iran)

^c KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Abuse treatment; Evaluation substance; Outcome study

Indexed keywords

EID: 85002374678     PISSN: None     EISSN: 23225939     Source Type: Journal    
DOI: 10.15171/ijhpm.2013.24     Document Type: Article

References (18)

1. UNODC. World Drug Report 2012. Vienna: United Nations Office on Drugs and Crime; 2012.
2. Nakhaee N, Divsalar K, Meimandi MS, Dabiri S. Estimating the prevalence of opiates use by unlinked anonymous urine drug testing: A pilot study in Iran. Subst Use Misuse 2008; 43: 513–20.
3. NIDA. Therapeutic Community: What is a Therapeutic Community? Bethesda, MD: National Institute on Drug Abuse; 2002.
4. UNODC. Evaluation of Substance Use Treatment Programmes. Vienna: United Nations Office on Drugs and Crime; 2009.
5. Malivert M, Fatséas M, Denis C, Langlois E, Auriacombe M. Effectiveness of therapeutic communities: A systematic review. Eur Addict Res 2012; 18: 1–11.
6. Marlatt GA, Gordon JR. Relapse prevention: maintenance strategies in the treatment of addictive behaviors. New York: Guilford Press; 1985.
7. Marsden J, Gossop M, Stewart D, Best D, Farrell M, Lehmann P, et al. The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome. Addiction 1998; 93:1857–68.
8. Afshari R, Zare I, Moeen L. [The effect of group schema therapy approach in improvement of B category personality disorders for substance dependents]. Journal of Psychological models and Methods 2011; 1: 19–35.
9. Autrique M, Vandeplasschen W, Broekaert E, Sabbe B. The drug-free therapeutic community: Findings and reflections in an evidence-based era. Therapeutic Communities: The International Journal of Therapeutic Communities 2008; 29: 5–15.
10. Miller WR, Sorensen JL, Selzer JA, Brigham GS. Disseminating Evidence-Based Practices in Substance Abuse Treatment: A Review with Suggestions. J Subst Abuse Treat 2006; 31: 25–39.
11. Johnson K, Pan Z, Young L, Vanderhoff J, Shamblen S, Browne T, et al. Therapeutic community drug treatment success in Peru: a follow-up outcome study. Subst Abuse Treat Prev Policy 2008; 3: 26.
12. Abdollahnejad MR. Follow-Up evaluation of Tehran Therapeutic Community. Therapeutic Communities: The International Journal of Therapeutic Communities 2008; 29: 57–75.
13. Darke S, Campbell G, Popple G. Retention, early dropout and treatment completion among therapeutic community admissions. Drug Alcohol Rev 2012; 31: 64–71.
14. Fernández Hermida JR, Secades Villa R, Fernández Ludeña JJ, Marina González PA. Effectiveness of a therapeutic community treatment in Spain: a long-term follow-up study. Eur Addict Res 2002; 8: 22–9.
15. Van Stelle KR, Blumer C, Moberg DP. Treatment retention of dually diagnosed offenders in an institutional therapeutic community. Behav Sci Law 2004; 22: 585–97.
16. Dekel R, Benbenishty R, Amram Y. Therapeutic communities for drug addicts: prediction of long-term outcomes. Addict Behav 2004; 29: 1833–7.
17. Carroll JF, McGinley JJ. An agency follow-up outcome study of graduates from four inner-city therapeutic community programs. J Subst Abuse Treat 2000; 18: 103–18.
18. Ziaaddini H, Nasirian M, Nakhaee N. Comparison of the efficacy of Buprenorphine and Clonidine in detoxification of opioid-dependents. Addict Health 2012; 4: 79–86.